Suppl. Fig. 2
description
Transcript of Suppl. Fig. 2
Suppl. Fig. 2
Cntrl
FasL25ng/ml
A
Pro-caspase 3
Actin
B
Cntr
l
zVA
D
0.5
FasL
25 F
asL
HuT
78
0.5
FasL
+zV
AD
25 F
asL
+zVA
D
Cntr
l
0.5
FasL
5 Fa
sL
25 F
asL
Cntr
l
α-Fa
s
25 F
asL
+α-F
as
zVA
D
25
FasL
+ zV
AD
Cntr
l
0.5
FasL
0.5
FasL
+zV
AD
25 F
asL
zVA
D
25 F
asL+
zVA
D
day 1 day 2 day 4 day 6day 6
35 KDa
43 KDa
Evaluation of FasL-induced apoptosis in BM-MSCs.A) BM-MSCs were plated on chamber slides at a density of 5×103 cells/cm2 and treated with 25 ng/ml FasL for 1, 2, 4, or 6 days. After fixation they were stained with Hoechst to show nuclei (arrows, pycnotic nuclei). B) Original caspase 3 western blots from batch # 1 BM-MSCs treated with 0.5 ng/ml FasL (0.5 FasL), 25 ng/ml FasL (25 FasL), or pretreated with the caspase inhibitor zVAD before FasL treatment (0.5 FasL zVAD, 25 FasL zVAD). Untreated cells (cntrl) and zVAD-supplemented cells (zVAD) were used as controls. HuT78 cell line treated with 25ng/ml FasL for 5 hours were used as caspase-3 activation positive control.
19/17 KDaactive fragments